# RBQM-ai

> RBQM-ai is Aomics' evidence-first risk-based quality management workspace for clinical-trial oversight. It supports qualified human reviewers with central monitoring, site prioritisation, KRI/QTL surveillance, governed data lineage and secure study communication; it does not make clinical decisions.

## Product

- [RBQM-ai overview](https://rbqm-ai.com/): Product scope, central monitoring approach and human-review boundaries.
- [Security](https://rbqm-ai.com/security): Security architecture, encryption, access controls and deployment responsibilities.
- [Data protection](https://rbqm-ai.com/data-protection): Privacy information, processing purposes and data-subject information.
- [Terms of use](https://rbqm-ai.com/terms): Permitted use and important limitations.

## Access and evaluation

- [Sign in](https://rbqm-ai.com/login): Access an authorised RBQM-ai workspace.
- [Request a demonstration](https://rbqm-ai.com/book-demo): Request a controlled product demonstration.
- [Request a quote](https://rbqm-ai.com/request-quote): Contact Aomics about a qualified deployment.
- [Investor information](https://rbqm-ai.com/investors): Company and investor information.

## Important use boundary

- RBQM-ai provides decision support to qualified clinical-trial professionals; human review and authorisation remain required.
- Public pages contain no participant-level clinical data. Authenticated study, site, connector, communication, audit and analytical routes are not public agent surfaces.
- A deployed instance is not automatically GxP validated, 21 CFR Part 11 compliant, ISO 27001 certified or SOC 2 attested. Applicability, validation, supplier qualification and operating procedures must be established for each intended use and deployment.

## Optional

- [Expanded product context](https://rbqm-ai.com/llms-full.txt): Longer machine-readable description of product capabilities, limitations and governance.
- [Public sitemap](https://rbqm-ai.com/sitemap.md): Human- and agent-readable list of public pages.